Merck Declares $0.85 Q2 Dividend, Highlights Winrevair and Keytruda Momentum
Merck’s board declared a quarterly dividend of $0.85 per share for second-quarter 2026, payable April 7 to shareholders of record on March 16. The stock’s rebound outlook is supported by clinical advances in Winrevair and CD388 and the commercial launch of subcutaneous Keytruda ahead of the 2028 patent cliff.
1. Board Declares Second-Quarter 2026 Dividend
Merck’s Board of Directors has approved a quarterly dividend of $0.85 per share of the company’s common stock for Q2 2026. The dividend will be paid on April 7, 2026, to shareholders of record as of the close of business on March 16, 2026. This marks the continuation of Merck’s long-standing commitment to returning capital to shareholders, reflecting the company’s robust cash flow generation from its leading oncology and vaccine franchises.